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OBJECTIVE—Phosphoinositide 3-kinase (PI3K) is a major ef-
fector in insulin signaling. rs361072, located in the promoter of
the gene (PIK3CB) for the p110 subunit, has previously been
found to be associated with homeostasis model assessment for
insulin resistance (HOMA-IR) in obese subjects. The aim was to
investigate the inﬂuence of rs361072 on in vivo glucose metabo-
lism, skeletal muscle PI3K subunit protein levels, and type 2
diabetes.
RESEARCH DESIGN AND METHODS—The functional role
of rs361072 was studied in 196 Danish healthy adult twins.
Peripheral and hepatic insulin sensitivity was assessed by a
euglycemic-hyperinsulinemic clamp. Basal and insulin-stimu-
lated biopsies were taken from the vastus lateralis muscle, and
tissue p110 and p85 proteins were measured by Western
blotting. The genetic association with type 2 diabetes and quan-
titative metabolic traits was investigated in 9,316 Danes with
glucose tolerance ranging from normal to overt type 2 diabetes.
RESULTS—While hepatic insulin resistance was similar in the
fasting state, carriers of the minor G allele had lower hepatic
glucose output (per-allele effect: 16%, Padd  0.004) during high
physiological insulin infusion. rs361072 did not associate with
insulin-stimulated peripheral glucose disposal despite a de-
creased muscle p85:p110 protein ratio (Padd  0.03) in G allele
carriers. No association with HOMA-IR or type 2 diabetes (odds
ratio 1.07, P  0.5) was identiﬁed, and obesity did not interact
with rs361072 on these traits.
CONCLUSIONS—Our study suggests that the minor G allele of
PIK3CB rs361072 associates with decreased muscle p85:p110
ratio and lower hepatic glucose production at high plasma insulin
levels. However, no impact on type 2 diabetes prevalence was
found. Diabetes 59:1108–1112, 2010
T
he phosphoinositide 3-kinase (PI3K) is a key
effector in the insulin signaling pathway, medi-
ating, among others, GLUT4 translocation to the
cell membrane in skeletal muscle and suppress-
ing hepatic glucose production (HGP). The enzyme con-
sists of regulatory p85 and catalytic p110 subunits existing
in different isoforms. In cultured ﬁbroblasts, the quantity
of p85 exceeds p110 (1). Free p85 is thought to compete
with the p85:p110 complex for phosphotyrosine sites on
insulin receptor substrate (IRS)-1. Furthermore, p85 may
activate phosphatase and tensin homolog, thereby attenu-
ating insulin signaling (2). The balance between p85 and
p110 subunits therefore seems to be critical for signaling
through the PI3K pathway (1,3). Hence, gene variants
altering transcriptional activity or protein function may
affect insulin sensitivity. We have previously shown that an
amino acid substitution (Met326Ile) in the p85 subunit
was associated with reduced glucose disappearance in
homozygous healthy Caucasians (4). rs361072 is a single-
nucleotide polymorphism (SNP) located at position 359
in the promoter of PIK3CB, the gene encoding the p110
subunit. This promoter region contains a motif for the
GATA family of transcription factors. Accordingly, the
minor G variant associates with enhanced transcriptional
activity, as evidenced by increased p110 mRNA and
protein levels in leukocytes (5). In Caucasians, the G allele
is common, with a frequency of 48%. Recent studies
involving 3,366 French children showed that G allele
carriers were protected from obesity-related insulin resis-
tance measured as homeostasis model assessment for
insulin resistance (HOMA-IR) (5,6). The effect was smaller
in 1,139 obese French adults (7), and in 295 normal-weight
Finnish adults, rs361072 did not associate with insulin
sensitivity (8).
The aims of the present study were to investigate the
functional role of PIK3CB rs361072 in metabolically well-
characterized Danish adult twins and to examine the
association of rs361072 with type 2 diabetes and quantita-
tive metabolic traits in a population-based sample of adult
Danes. In addition, we aimed to investigate the potential
interaction of the p85 (PIK3R1) Met326Ile variant with
rs361072 on insulin sensitivity.
RESEARCH DESIGN AND METHODS
In vivo metabolism and heritability were investigated in 196 monozygotic (MZ
group; n  108) and same-sex dizygotic (DZ group; n  88) Danish twins
without known type 2 diabetes, previously described in detail (9). Subjects
were identiﬁed having normal glucose tolerance (NGT; n  172), impaired
glucose tolerance (IGT; n  21), and screen-detected type 2 diabetes (n  3),
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related quantitative traits were investigated in 5,750 subjects from the Danish
population-based Inter99 cohort (11), including individuals with NGT (n 
4,275), impaired fasting glycemia (n  476), IGT (n  650), and screen-
detected type 2 diabetes (n  235), according to WHO criteria. Subjects with
known type 2 diabetes (n  114) were excluded from analyses of quantitative
traits. The genetic association with type 2 diabetes was assessed in a
case-control material including all unrelated type 2 diabetes case and healthy
control individuals from the Inter99 sample (case subjects: n  313, control
subjects: n  4,275), conﬁrmed type 2 diabetic subjects from the ADDITION
(Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-
Detected Diabetes in Primary Care) Denmark screening study samples (case
subjects: n  1,577) (12), and type 2 diabetic patients and glucose-tolerant
individuals recruited from the outpatient clinic at Steno Diabetes Center (case
subjects: n  1,494, control subjects: n  495). All study participants had
provided informed written consent, and the study was approved by the
regional ethical committees and conducted in accordance with the principles
of the Helsinki Declaration II.
Clinical examination. All subjects underwent measures of height and weight
for calculation of BMI, and a WHO-deﬁned and standardized oral glucose
tolerance test (OGTT) was conducted in subjects without known type 2
diabetes. In addition, the twins underwent a dual-energy X-ray absorptiometry
scan with measurement of total body fat percentage, a 2-h (40 mU/m
2 per min)
euglycemic-hyperinsulinemic clamp, and an intravenous glucose tolerance
test (IVGTT) (9). Biopsies were excised from the vastus lateralis muscle (n 
184) during the basal and insulin-stimulated states (13). Plasma glucose and
serum insulin were measured as previously described (9). The hepatic insulin
resistance index was calculated as basal HGP  fasting serum insulin,
and HOMA-IR as fasting serum insulin (pmol/l)  fasting plasma glucose
(mmol/l)/22.5. OGTT-derived indexes for acute insulin response (BIGTT-AIR)
and insulin sensitivity (BIGTT-Si) were calculated as described previously
(14). The BIGTT indexes apply information on sex and BMI combined with
plasma glucose and serum insulin during an OGTT to provide indexes for AIR
and Si that are highly correlated with indexes obtained during an IVGTT.
-Cell function was evaluated as the disposition index (Di) for peripheral
insulin action calculated from IVGTT and clamp data (9) or as BIGTT-AIR 
BIGTT-Si.
Genotyping. Genotyping of PIK3CB rs361072 and PIK3R1 rs3730089 was
performed by KASPar SNP Genotyping (KBiosciences, Hoddesdon, U.K.),
with success rates of 95.7 and 96.8%, respectively. Discordance was 0.34%
for rs361072 and 0.84% for rs3730089, as judged from regenotyping of 893
random duplicate samples. Both variants obeyed the Hardy-Weinberg
equilibrium (P  0.3).
Muscle protein expression. p85 and p110 contents were determined by
Western blotting described in the online appendix (available at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-1359/DC1).
Statistical methods. Statistical analyses were performed using R version
2.7.2 (available at http://www.r-project.org) and SAS version 9.1 (SAS Insti-
tute, Cary, NC). Heritability (h
2), giving the proportion of the total variation of
a trait attributable to genetic variation, was calculated from the intraclass
correlations of MZ and DZ twins (h
2  2[rMZ  rDZ]) (15). Linear models,
assuming an additive allele effect, were used to test for associations of
genotypes with quantitative traits. Adjustment for twin zygosity and pair
status was performed using the SAS PROC MIXED. If not otherwise stated, P
values (Padd) are adjusted for sex, age, and body fat percentage (BMI in
singletons). Interaction analyses compared a two-SNP additive model with a
model including additive SNP interaction. Statistical signiﬁcance was deﬁned
as P  0.05. Results are presented as means  SD, and odds ratios are
reported with 95% CI.
RESULTS
Association of PIK3CB rs361072 with in vivo metab-
olism and type 2 diabetes. No differences were identi-
ﬁed in BMI, body fat percentage, fasting serum insulin, and
fasting plasma glucose among the PIK3CB rs361072 geno-
type groups (Tables 1 and 2). In the Inter99 sample,
rs361072 was associated with 30-min post-OGTT plasma
glucose with subjects carrying the GG alleles having the
lowest value, whereas 2-h plasma glucose was similar. In
the twins, the G allele was associated with enhanced
insulin suppression of HGP but not with basal HGP or
hepatic insulin resistance index. In addition, rs361072 was
not associated with insulin-stimulated glucose disposal
(Rd) in the twins or indexes of insulin sensitivity in the
Inter99 sample. Further stratiﬁcation of the Inter99 popu-
lation in lean (BMI 25 kg/m
2), overweight (25 kg/m
2 
BMI  30 kg/m
2), and obese (BMI 30 kg/m
2) subjects did
not change the result (Padd  0.6), and no interaction of
BMI with rs361072 on HOMA-IR (P  0.9) or BIGTT-Si
(P  0.5) was evident. No association was found between
rs361072 and Di. In the case-control study, rs361072 was
not associated with type 2 diabetes (Table 3).
Interaction of PIK3R1 rs3730089 with PIK3CB
rs361072. PIK3R1 rs3730089 did not associate with any
glucose metabolic trait in the twin sample, whereas the
minor A allele was associated with improved HOMA-IR
and BIGTT-Si in Inter99 subjects (online appendix Tables
1 and 2). rs3730089 did not interact with rs361072 on
HOMA-IR (P  0.7) or BIGTT-Si (P  0.3).
Association of PIK3CB rs361072 with muscle PI3K
protein. The intraclass correlation coefﬁcients for insulin-
stimulated p85 were rMZ  0.70 and rDZ  0.57, giving a
TABLE 1
Characteristics of twin subjects stratiﬁed according to PIK3CB rs361072 genotypes
PIK3CB rs361072 AA GA GG Padd
Genotype frequency (%) 30.4 45.6 24.1 —
n (male/female) 58 (23/35) 87 (42/45) 46 (30/16) —
Age (years) 44.4  17.4 42.6  16.9 41.2  16.8 —
BMI (kg/m
2) 24.5  3.7 25.6  4.1 24.8  3.7 0.6
Fat percentage 24.8  8.1 25.7  9.3 22.9  7.7 0.3
Fasting insulin (pmol/l) 33.2  17.7 36.6  20.4 34.7  17.6 0.9
30-min insulin (pmol/l) 287.7  129.0 347.4  203.2 334.1  169.9 0.2
120-min insulin (pmol/l) 192.4  193.9 177.2  106.8 154.8  91.0 0.5
Fasting glucose (mmol/l) 5.4  0.8 5.4  0.6 5.3  0.5 0.6
30-min glucose (mmol/l) 8.5  2.0 8.6  1.7 8.4  1.3 0.9
120-min glucose (mmol/l) 6.7  2.4 6.4  1.3 6.3  1.3 0.4
Rd clamp (mg  kg fat-free mass
1  min
1) 11.8  3.4 10.5  3.3 10.5  3.5 0.2
HGP clamp (mg  kg fat-free mass
1  min
1) 1.7  0.6 1.5  0.5 1.4  0.6 0.004
HGP basal (mg  kg fat-free mass
1  min
1) 3.1  0.4 3.1  0.5 2.9  0.4 0.3
Hepatic insulin resistance index 104.3  57.8 112.9  60.0 101.4  54.0 0.7
Di 1.7  1.1  10
7 1.8  1.0  10
7 1.7  1.5  10
7 0.9
Data are means  SD. Association of PIK3CB rs361072 with quantitative traits is shown in 191 Danish twins. All Padd values are adjusted for
sex, age, and twin-pair and zygosity status. Padd values for plasma levels of glucose and insulin and for metabolic rates and indexes are
additionally adjusted for body fat percentage.
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2  0.25. The similar values for insulin-
stimulated p110 were rMZ  0.44 and rDZ  0.28, h
2 
0.33. rs361072 did not associate with p110 protein levels,
but carriers of the G allele had decreased p85 and a lower
p85:p110 protein ratio at insulin-stimulated conditions
(Table 4). PIK3R1 rs3730089 did not associate with p85
and p110 protein levels or their ratio (online appendix
Table 3). Insulin-stimulated p85 (P  0.4), p110 (P 
0.8), or p85:p110 (P  0.4) were not associated with Rd.
DISCUSSION
Applying the euglycemic-hyperinsulinemic clamp, we dem-
onstrate that the minor G allele of PIK3CB rs361072
associates with enhanced suppression of HGP and de-
creased p85:p110 protein ratio in skeletal muscle during
insulin infusion. However, in the large-scale case-control
study, we were unable to demonstrate any association of
the G allele with type 2 diabetes.
Previous studies (5–7) have shown that the G allele of
rs361072 associates with improved HOMA-IR in obese
subjects but not with insulin-stimulated glucose disposal
in normal-weight adults (8). Therefore, a role of rs361072
in the development of type 2 diabetes in only obese
individuals has been proposed (5). Our present data,
however, do not suggest obesity to determine genotype
penetrance in adults. The discrepancy between studies
using surrogate versus clamp measures of insulin sensitiv-
ity may also be explained by the fact that HOMA-IR is
inﬂuenced predominantly by hepatic insulin resistance
(16). Therefore, we examined the association of rs361072
with hepatic insulin sensitivity measured by a euglycemic-
hyperinsulinemic clamp at physiological plasma insulin
levels. The G allele was associated with a decrease in HGP
of 16% during insulin infusion, independent of age and
obesity, whereas no inﬂuence of rs361072 was seen on
hepatic insulin resistance index, indicating a negligible
role of genotype at fasting conditions. Given a more
pronounced effect of rs361072 at high plasma insulin
levels, it could explain the lack of association with
HOMA-IR in our study of 5,635 middle-aged Danes. How-
ever, the G allele was associated with lower 30-min
post-OGTT plasma glucose. At this time point, plasma
insulin peaks, and the glucose- and insulin-mediated sup-
pression of HGP has been shown to reach its maximum
(17). Therefore, an improved suppression of HGP in G
allele carriers might contribute to the decrease in 30-min
plasma glucose. Our data do not suggest a role of rs361072
in the regulation of peripheral insulin sensitivity.
Among the currently 20 known type 2 diabetes sus-
ceptibility genes, most affect -cell function, whereas few,
including IRS1, associate predominantly with insulin re-
sistance (18). The genetic contribution to insulin resis-
tance may be masked by the inﬂuence of environmental
factors or by the ability of healthy -cells to compensate
(19). As reported previously (7), PIK3CB rs361072 was not
associated with type 2 diabetes, even in obese subjects,
TABLE 2
Characteristics of Inter99 subjects stratiﬁed according to PIK3CB rs361072 genotypes
PIK3CB rs361072 AA GA GG Padd
Genotype frequency (%) 28.6 50.0 21.4 —
n (male/female) 1,613 (824/789) 2,816 (1,400/1,416) 1,206 (584/622) —
Age (years) 46.3  8.0 46.1  7.8 45.9  7.7 —
BMI (kg/m
2) 26.2  4.5 26.2  4.6 26.1  4.5 0.7
Fasting insulin (pmol/l) 41.0  26.4 42.4  28.7 41.8  28.1 0.3
30-min insulin (pmol/l) 292.0  178.0 287.6  176.8 296.0  203.5 0.9
120-min insulin (pmol/l) 213.9  213.5 219.2  212.0 214.0  208.0 0.4
Fasting glucose (mmol/l) 5.6  0.9 5.5  0.8 5.5  0.7 0.2
30-min glucose (mmol/l) 8.8  1.9 8.7  1.9 8.6  1.8 0.001
120-min glucose (mmol/l) 6.2  2.2 6.2  2.1 6.2  2.0 0.6
HOMA-IR 10.4  7.7 10.7  8.4 10.4  7.6 0.5
BIGTT-Si 9.2  4.0 9.2  4.1 9.3  4.2 0.4
BIGTT-AIR 1,805.4  934.9 1,851.7  1,124.2 1,872.5  1,072.3 0.1
Di 15,090.3  7,024.1 15,413.6  7,363.0 15,785.8  7,195.3 0.1
Data are means  SD. Association of PIK3CB rs361072 with quantitative traits in 5,635 Danish subjects. All Padd values are adjusted for sex
and age. Padd values for plasma levels of glucose and insulin, HOMA-IR, BIGTT-Si, and BIGTT-AIR are additionally adjusted for BMI.
TABLE 3
Association of PIK3CB rs361072 with type 2 diabetes
SNP
Allele
(minor/major)
Minor allele
frequency (%) Genotype
Genotype distribution
Odds ratio (95% CI) NGT
Type 2
diabetes
PIK3CB rs361072 (G/A) 47 AA 1,353 (28%) 940 (28%) 1.07 (0.96–1.09); P  0.5
GA 2,375 (50%) 1,673 (49%)
GG 1,042 (22%) 771 (23%)
Individuals with BMI 30 kg/m
2
PIK3CB rs361072 (G/A) 47 AA 163 (29%) 484 (28%) 1.11 (0.94–1.31); P  0.2
GA 283 (50%) 843 (49%)
GG 120 (21%) 385 (22%)
Odds ratios are shown with 95% CI for all subjects and for the subgroup of obese subjects. The association study involved 3,384 type 2
diabetic patients and 4,770 glucose-tolerant control participants. P values are adjusted for sex, age, and BMI.
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by the fact that the suppressing effect of the G allele on
HGP is evident at high physiological plasma insulin levels
only and that the variant does not affect insulin secretion.
Heritability estimates demonstrated a genetic contribu-
tion to variance of 25–33% for p85 and p110 protein
levels, suggesting a major role of environmental factors in
their regulation in skeletal muscle. Accordingly, we did not
ﬁnd an association of rs361072 with p110 muscle protein.
Thus, an additional GATA binding site, created by the G
variant, may not be sufﬁcient to alter gene expression to a
degree that is measurable at the protein level. Surprisingly,
subjects homozygous for the A allele had an increase of
p85 and a higher p85:p110 ratio during insulin infusion
than GG subjects. Several studies have shown that p110
and p85 are coregulated, and p85 levels may change more
dynamically than those of p110 (20,21). Therefore, the
p110 variant could possibly play a role in the regulation
of p85 expression. A high p85:p110 ratio has been shown
to associate with insulin resistance (22), and p85 has been
found upregulated in patients with type 2 diabetes (23).
We failed to demonstrate an association between muscle
p85:p110 ratio and insulin-stimulated glucose disposal;
it is speculated, however, that the improved hepatic insu-
lin sensitivity in G allele carriers might relate to the
hepatic p85:p110 ratio.
Our previous in vitro study of the p85 Met326Ile
substitution (rs3730089) showed that the minor A allele
was associated with signiﬁcantly decreased p85 expres-
sion in yeast, whereas the decrease was modest in brown
preadipocytes (24). Theoretically, a slight reduction of
p85 in A allele carriers could explain the improved
insulin sensitivity found in the Inter99 sample. However, in
skeletal muscle, p85 levels were similar among the
genotypes, and as shown previously (25), the variant was
not associated with peripheral insulin sensitivity as mea-
sured by a euglycemic-hyperinsulinemic clamp. Even
though both rs361072 and rs3730089 showed some asso-
ciation with insulin sensitivity, they did not interact.
In conclusion, we demonstrate that the minor G allele of
the common PIK3CB rs361072 associates with improved
hepatic, but not peripheral, insulin sensitivity or type 2
diabetes. The variant does not inﬂuence p110 muscle
protein expression but may indirectly play a role in the
regulation of p85 subunit expression.
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